L. Agostinho, R. Cruz, F. Osório, J. Alves, A. Setúbal et al., MRI for adenomyosis: a pictorial review, Insights Imaging. déc, vol.8, issue.6, pp.549-56, 2017.

A. M. Siegler, L. Camilien, and . Adenomyosis, J Reprod Med. nov, vol.39, issue.11, pp.841-53, 1994.

G. Benagiano, M. Habiba, and I. Brosens, The pathophysiology of uterine adenomyosis: an update, Fertil Steril. sept, vol.98, issue.3, pp.572-581, 2012.

M. Bazot and E. Daraï, Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis, Fertil Steril. mars, vol.109, issue.3, pp.389-97, 2018.

K. Tamai, T. Koyama, S. Umeoka, T. Saga, S. Fujii et al., Spectrum of MR features in adenomyosis, Best Pract Res Clin Obstet Gynaecol. août, vol.20, issue.4, pp.583-602, 2006.

M. Gracia, M. Alcalà, J. Ferreri, M. Rius, R. C. Saco et al., Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas, J Minim Invasive Gynecol, vol.25, issue.7, pp.1274-80, 2018.

L. Garcia and K. Isaacson, Adenomyosis: review of the literature, J Minim Invasive Gynecol. août, vol.18, issue.4, pp.428-465, 2011.

R. Champaneria, P. Abedin, J. Daniels, M. Balogun, and K. S. Khan, Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy, Acta Obstet Gynecol Scand, vol.89, issue.11, pp.1374-84, 2010.

A. Pourcelot, P. Capmas, and H. Fernandez, Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?, J Gynecol Obstet Hum Reprod. mars, vol.46, issue.3, pp.249-54, 2017.

M. Powell and D. Dutta, Esmya ® and the PEARL studies: A review. Womens Health, vol.12, pp.544-552, 2016.

J. Donnez, P. Bouchard, N. F. Zakharenko, G. Ugocsai, E. Bestel et al., Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery, N Engl J Med, vol.12, 2012.

J. Donnez, J. Tomaszewski, F. Vázquez, P. Bouchard, B. Lemieszczuk et al.,

, Ulipristal acetate versus leuprolide acetate for uterine fibroids, N Engl J Med. 2 févr, vol.366, issue.5, pp.421-453, 2012.

J. Donnez, F. Vázquez, J. Tomaszewski, K. Nouri, P. Bouchard et al., Longterm treatment of uterine fibroids with ulipristal acetate ?, Fertil Steril. juin, vol.101, issue.6, pp.1565-1573, 2014.

G. L. Mutter, C. Bergeron, L. Deligdisch, A. Ferenczy, M. Glant et al., The spectrum of endometrial pathology induced by progesterone receptor modulators, Mod Pathol. mai, vol.21, issue.5, pp.591-599, 2008.

J. Donnez, O. Donnez, and M. Dolmans, Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate, Expert Opin Drug Saf. déc, vol.15, issue.12, pp.1679-86, 2016.

I. De-milliano, D. Van-hattum, J. Ket, J. Huirne, and W. Hehenkamp, Endometrial changes during ulipristal acetate use: A systematic review, Eur J Obstet Gynecol Reprod Biol. juill, vol.214, pp.56-64, 2017.

J. Donnez and M. Dolmans, Uterine fibroid management: from the present to the future, Hum Reprod Update, vol.22, issue.6, pp.665-86, 2016.

F. Conway, G. Morosetti, S. Camilli, F. G. Martire, G. Sorrenti et al., Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids, Gynecol Endocrinol. nov, pp.1-4, 2018.

, Adenomyosis and Ulipristal Acetate (FRA-IIT-UPA)

S. S. Singh, L. Belland, N. Leyland, S. Von-riedemann, and A. Murji, The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids, Am J Obstet Gynecol. juin, vol.218, issue.6, pp.563-572, 2018.

M. Bazot, J. Nassar-slaba, J. Rouger, A. Cortez, and E. Daraï, Imagerie de l'adénomyose. EMC -Gynécologie-Obstétrique, août, vol.2, issue.3, pp.269-77, 2005.

J. Ochi, K. Hayakawa, Y. Moriguchi, Y. Urata, A. Yamamoto et al., Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging, Jpn J Radiol. juill, vol.28, issue.6, pp.430-436, 2010.

A. Williams, C. Bergeron, D. H. Barlow, and A. Ferenczy, Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, p.25

, ulipristal acetate, Int J Gynecol Pathol Off J Int Soc Gynecol Pathol, vol.31, issue.6, pp.556-69, 2012.

J. Donnez, P. Arriagada, M. Marciniak, and D. Larrey, Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program, Expert Opin Drug Saf. 2 déc, vol.17, issue.12, pp.1225-1257, 2018.

J. Donnez, Liver injury and ulipristal acetate: an overstated tragedy?, Fertil Steril, vol.110, issue.4, pp.593-598, 2018.

L. Agostinho, R. Cruz, F. Osório, J. Alves, A. Setúbal et al., MRI for adenomyosis: a pictorial review, Insights Imaging. déc, vol.8, issue.6, pp.549-56, 2017.

A. M. Siegler, L. Camilien, and . Adenomyosis, J Reprod Med. nov, vol.39, issue.11, pp.841-53, 1994.

G. Benagiano, M. Habiba, and I. Brosens, The pathophysiology of uterine adenomyosis: an update, Fertil Steril. sept, vol.98, issue.3, pp.572-581, 2012.

M. Bazot and E. Daraï, Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis, Fertil Steril. mars, vol.109, issue.3, pp.389-97, 2018.

K. Tamai, T. Koyama, S. Umeoka, T. Saga, S. Fujii et al., Spectrum of MR features in adenomyosis, Best Pract Res Clin Obstet Gynaecol. août, vol.20, issue.4, p.602, 2006.

M. Gracia, M. Alcalà, J. Ferreri, M. Rius, R. C. Saco et al., Ulipristal Acetate Improves Clinical Symptoms in Women with Adenomyosis and Uterine Myomas, J Minim Invasive Gynecol, vol.25, issue.7, p.80, 2018.

L. Garcia and K. Isaacson, Adenomyosis: review of the literature, J Minim Invasive Gynecol. août, vol.18, issue.4, pp.428-465, 2011.

R. Champaneria, P. Abedin, J. Daniels, M. Balogun, and K. S. Khan, Ultrasound scan and magnetic resonance imaging for the diagnosis of adenomyosis: systematic review comparing test accuracy, Acta Obstet Gynecol Scand, vol.89, issue.11, pp.1374-84, 2010.

A. Pourcelot, P. Capmas, and H. Fernandez, Place of ulipristal acetate in the management of uterine fibroids: Preoperative treatment or sequential treatment?, J Gynecol Obstet Hum Reprod. mars, vol.46, issue.3, pp.249-54, 2017.

M. Powell and D. Dutta, Esmya ® and the PEARL studies: A review. Womens Health, vol.12, pp.544-552, 2016.

J. Donnez, P. Bouchard, N. F. Zakharenko, G. Ugocsai, E. Bestel et al., Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery, N Engl J Med, vol.12, 2012.

J. Donnez, J. Tomaszewski, F. Vázquez, P. Bouchard, B. Lemieszczuk et al., Ulipristal acetate versus leuprolide acetate for uterine fibroids, N Engl J Med. 2 févr, vol.366, issue.5, pp.421-453, 2012.

J. Donnez, F. Vázquez, J. Tomaszewski, K. Nouri, P. Bouchard et al., Longterm treatment of uterine fibroids with ulipristal acetate ?, Fertil Steril. juin, vol.101, issue.6, pp.1565-1573, 2014.

G. L. Mutter, C. Bergeron, L. Deligdisch, A. Ferenczy, M. Glant et al., The spectrum of endometrial pathology induced by progesterone receptor modulators, Mod Pathol. mai, vol.21, issue.5, pp.591-599, 2008.

J. Donnez, O. Donnez, and M. Dolmans, Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate, Expert Opin Drug Saf. déc, vol.15, issue.12, pp.1679-86, 2016.

I. De-milliano, D. Van-hattum, J. Ket, J. Huirne, and W. Hehenkamp, Endometrial changes during ulipristal acetate use: A systematic review, Eur J Obstet Gynecol Reprod Biol. juill, vol.214, pp.56-64, 2017.

J. Donnez and M. Dolmans, Uterine fibroid management: from the present to the future, Hum Reprod Update, vol.22, issue.6, pp.665-86, 2016.

F. Conway, G. Morosetti, S. Camilli, F. G. Martire, G. Sorrenti et al., Ulipristal acetate therapy increases ultrasound features of adenomyosis: a good treatment given in an erroneous diagnosis of uterine fibroids, Gynecol Endocrinol. nov, vol.1, p.4, 2018.

, Adenomyosis and Ulipristal Acetate (FRA-IIT-UPA)

S. S. Singh, L. Belland, N. Leyland, S. Von-riedemann, and A. Murji, The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids, Am J Obstet Gynecol. juin, vol.218, issue.6, pp.563-572, 2018.

J. Ochi, K. Hayakawa, Y. Moriguchi, Y. Urata, A. Yamamoto et al., Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging, Jpn J Radiol. juill, vol.28, issue.6, pp.430-436, 2010.

M. Bazot, J. Nassar-slaba, J. Rouger, A. Cortez, and E. Daraï, Imagerie de l'adénomyose. EMCGynécologie-Obstétrique, août, vol.2, issue.3, pp.269-77, 2005.

A. Williams, C. Bergeron, D. H. Barlow, and A. Ferenczy, Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate, Int J Gynecol Pathol Off J Int Soc Gynecol Pathol, vol.31, issue.6, pp.556-69, 2012.

J. Donnez, P. Arriagada, M. Marciniak, and D. Larrey, Liver safety parameters of ulipristal acetate for the treatment of uterine fibroids: a comprehensive review of the clinical development program, Expert Opin Drug Saf. 2 déc, vol.17, issue.12, pp.1225-1257, 2018.

J. Donnez, Liver injury and ulipristal acetate: an overstated tragedy?, Fertil Steril, vol.110, issue.4, pp.593-598, 2018.